Cargando…

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies

In general, the course of schizophrenia is chronic accompanied not only by positive and negative symptoms but also by cognitive dysfunction associated with psychosocial disability, and thus treatment combining antipsychotics and psychological therapy is considered promising. This review focused on t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murasaki, Mitsukuni, Inoue, Yoshifumi, Nakamura, Hiroshi, Kinoshita, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425119/ https://www.ncbi.nlm.nih.gov/pubmed/34493318 http://dx.doi.org/10.1186/s12991-021-00361-3

Ejemplares similares

Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8‐week, double‐blind, multicenter, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
por: Saito, Takuya, et al.
Publicado: (2022)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
por: Hori, Hikaru, et al.
Publicado: (2014)

Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Saito, Takuya, et al.
Publicado: (2022)

Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression
por: Kanba, Shigenobu, et al.
Publicado: (2019)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study
por: Harvey, Philip D., et al.
Publicado: (2019)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

PM498. Investigation of feelings toward taking blonanserin and risperidone in schizophrenia patients: part 2
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D(2) Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Deng, Shu-Wen, et al.
Publicado: (2023)

Self-Regulatory Neuronal Mechanisms and Long-Term Challenges in Schizophrenia Treatment
por: Markiewicz-Gospodarek, Agnieszka, et al.
Publicado: (2023)

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
por: Karson, Craig, et al.
Publicado: (2016)

Striatal Dopamine D(2) Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia
por: Nishibe, Hironori, et al.
Publicado: (2020)

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2014)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
por: Zheng, Yunliang, et al.
Publicado: (2014)

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial
por: Pu, Chengcheng, et al.
Publicado: (2022)

Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature
por: Masumori, Naoya
Publicado: (2013)

A case of delusional parasitosis responded to blonanserin
por: Rathi, Anubhav, et al.
Publicado: (2018)

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication
por: Kinoshita, Toshihiko, et al.
Publicado: (2023)

Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study
por: Krzystanek, Marek, et al.
Publicado: (2017)

Long-term treatment with clozapine and verbal memory performance in schizophrenia
por: Czepielewski, Letícia S., et al.
Publicado: (2018)

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients
por: Sakayori, Takeshi, et al.
Publicado: (2020)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities
por: Okazaki, Kosuke, et al.
Publicado: (2016)

Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis
por: Yamada, Satoshi, et al.
Publicado: (2015)

A Simple and Sensitive HPLC-MS/MS Assay for the Quantitation of Blonanserin and N-Desethyl Blonanserin in Rat Plasma and Its Application to Pharmacokinetic Study
por: Huang, Shan-qing, et al.
Publicado: (2022)

Long‐term safety and efficacy of nalmefene in Japanese patients with alcohol dependence
por: Higuchi, Susumu, et al.
Publicado: (2020)

One-Year Follow-Up of Serum Prolactin Level in Schizophrenia Patients Treated with Blonanserin: A Case Series
por: Takahashi, Sakae, et al.
Publicado: (2015)

Medical care and long-term treatment of patients with schizophrenia: ethical concerns
por: do Couto, Frederico Simões
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bbmkgh9eb3c6manmrv3a7pjach